[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  EarningsTime [@Earnings_Time](/creator/twitter/Earnings_Time) on x 8375 followers Created: 2025-05-01 12:46:20 UTC Alnylam Pharmaceuticals, $ALNY, Q1-25. Results: 🟢 +2% Pre-Market ($268.56) 📊 Adj. EPS: -$0.01 🟢 💰 Revenue: $594M 🟢 🔎 FDA approved AMVUTTRA for ATTR-CM; strong commercial launch underway and sixth RNAi therapy, Qfitlia, also approved in U.S.  XXX engagements  **Related Topics** [underway](/topic/underway) [$594m](/topic/$594m) [eps](/topic/eps) [$alny](/topic/$alny) [alnylam pharmaceuticals inc](/topic/alnylam-pharmaceuticals-inc) [stocks healthcare](/topic/stocks-healthcare) [Post Link](https://x.com/Earnings_Time/status/1917923541888151925)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
EarningsTime @Earnings_Time on x 8375 followers
Created: 2025-05-01 12:46:20 UTC
Alnylam Pharmaceuticals, $ALNY, Q1-25. Results: 🟢 +2% Pre-Market ($268.56)
📊 Adj. EPS: -$0.01 🟢 💰 Revenue: $594M 🟢 🔎 FDA approved AMVUTTRA for ATTR-CM; strong commercial launch underway and sixth RNAi therapy, Qfitlia, also approved in U.S.
XXX engagements
Related Topics underway $594m eps $alny alnylam pharmaceuticals inc stocks healthcare
/post/tweet::1917923541888151925